As biopharma awaits Roche’s pivotal Skyscraper-01 data Arcus gives its investors some more tea leaves to read.
Roche just showed that adding Tigit to PD-(L)1 blockade is a non-starter in SCLC, and now Merck & Co risks doing the same.
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
Gilead opts in at long last, and that’s more than many might have been expecting.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?